We tested the peroxisome proliferator-activated receptor (PPAR) agonistic activity of a Garcinia mangostana pericarp extract to develop a treatment for the metabolic syndrome, and demonstrated -mangostin to be an active compound on the basis of a luciferase reporter gene assay. -Mangostin induced the expression of the uncoupling protein-3 (UCP-3) gene which is related to energy expenditure and fat metabolism in L6 cells. We showed that -mangostin is a dual agonist that activates both PPAR and PPAR.
We tested the peroxisome proliferator-activated receptor (PPAR) agonistic activity of a Garcinia mangostana pericarp extract to develop a treatment for the metabolic syndrome, and demonstrated -mangostin to be an active compound on the basis of a luciferase reporter gene assay. -Mangostin induced the expression of the uncoupling protein-3 (UCP-3) gene which is related to energy expenditure and fat metabolism in L6 cells. We showed that -mangostin is a dual agonist that activates both PPAR and PPAR.
-Mangostin also induced the expression of acyl-CoA synthase and carnitine palmitoyl-transferase 1A genes in HepG2 cells. These results suggest the potential of -mangostin as a preventive agent of the metabolic syndrome.
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Peroxisome proliferator-activated receptors (PPARs) belong to a subfamily of the nuclear receptor superfamily and are ligand-activated transcription factors that heterodimerize with the retinoid X receptor and bind to the PPAR response element which is localized in the promoter regions of target genes. 1) Three sub-types of PPAR have been identified: PPAR, PPAR and PPAR. PPAR is involved in controlling the lipid metabolism in the liver and skeletal muscles. A PPAR agonist such as bezafibrate reduces the triglyceride level but increases the plasma HDL-cholesterol level. 2) PPAR is ubiquitously expressed and is thought to be involved in cell proliferation.
3) Furthermore, it has been shown that PPAR activation induced the gene expression required for fatty acid oxidation and energy dissipation, thus improving the lipid profile and reducing adipocity. 4) No PPAR agonists have been developed with clinical potential, although it has recently been reported that PPAR is a potential therapeutic target for the metabolic syndrome, insulin resistance, and obesity. 5) In particular, GW501516 is a PPAR agonist that normalizes the lipid level of patients with mixed dyslipidemia, according to the first phase IIa clinical trial. In vivo studies have shown that GW501516 induced fatty acid -oxidation in skeletal muscle and attenuated the metabolic syndrome. These reports show that PPAR agonists may have an important role in treating anti-obesity. PPAR is strongly expressed in adipocytes and is responsible for adipogenesis. Its agonists such as thiazolidinedione derivatives (pioglitazone and rosiglitaozone) are potent insulin sensitizers and can be used for treating type 2 diabetes. 6) The major causes of mortality in patients with diabetes mellitus are cardiovascular disorders. PPAR/ agonists are being developed to increase insulin sensitivity and to simultaneously prevent diabetic cardiovascular complications. 7) Some dual agonists promote cardiovascular risks and carcinogenicity. However, the cardioprotective role of PPAR has been elucidated in basic ongoing studies. Further research should therefore be focused on the development of PPAR/ and PPAR/ dual agonists.
Garcinia mangostana Linn. is a tree found in South East Asia, and its pericarps have been used as traditional medicine. Phytochemical studies have shown that they contained such secondary metabolites as oxygenated and prenylated xanthones (, , , and methoxy--mangostins). 8) Many studies have shown that these xanthones had such biological activities as anti-inflammatory, antibacterial, and anticancer effects. 9) A recent study has shown that -mangostin inhibited the proliferation of human colon cancer DLD cells, and its effects were associated with cell-cycle arrest by affecting cyclins, cdc2, and p27 expression. It has been reported that -mangostin had a cancer prevention effect in a rat carcinogenesis bioassay. 10) Furthermore, Shibata et al. have revealed that -mangostin significantly suppressed lymph node metastasis in a mouse mammary cancer model. 11) These results show the antimetastatic activity of -mangostin as detected in mammary cancers carrying a p53 mutation, and it may have chemopreventive benefits and/or prove useful as an adjuvant therapy, or as a complementary alternative medicine in the treatment of breast cancer.
We aimed to develop a PPAR agonist from natural resources, and then examined the PPAR agonist activity of 1,200 species of natural plant extracts. We found that the extract of G. mangostana pericarps showed PPAR _ agonist activity. We examined in this present study which compounds in an extract of G. mangostana pericarps would contribute to PPAR agonist activity, and also investigated the selectivity of the PPARs agonist activity exhibited by the active compound of -mangostin.
Materials and Methods
Chemicals. Dulbecco's modified Eagle's medium (DMEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Wy14643 and troglitazone were obtained from Cayman Chemicals (Michigan, USA), and GW0742 was obtained from Tocris Cookson (Missouri, USA). Fetal bovine serum (FBS) was obtained from PAA Laboratories (Pasching, Austria), and the other reagents were obtained from Nakalai Tesque (Kyoto, Japan). The H 2 O extract of G. mangostana pericarps was obtained from Field and Device Co. (Osaka, Japan). -andMangostins were isolated from G. mangostana, 8) Caloxanthone A and macluraxathantone were isolated from Calophyllum inophyllum, 12) subelliptenone A and 12 -hydroxy-des-D-garcigerin were isolated from G. subelliptica, 13) and harunganol B was isolated from Harungana madagascariensis, 14) as described previously. All the chemical reagents were dissolved in dimethyl sulfoxide (DMSO) and kept to À20 C until needed.
Cell culture. COS-1 cells were obtained from RIKEN Bioresource Center (Ibaraki, Japan). Rat skeletal muscle L6 cells and human hepatocellular carcinoma HepG2 cells were supplied by Health Science Research Resources Bank (Osaka, Japan). All the cell strains were maintained at 37 C in DMEM supplemented with 10% FBS in a 5% CO 2 -95% air incubator.
To differentiate the L6 cells into myotubes, 3 Â 10 3 cells were seeded into 30-mm dishes and treated for 48 h in a medium containing 2% FBS. After exchanging the medium containing 0.1% FBS with a medium containing the test compound or DMSO, the cells were incubated for 48 h, and then total RNA was isolated as described later.
Next, 2 Â 10 5 of HepG2 cells were maintained in 60-mm culture dishes, and 1 mg of the human PPAR expression vector, pDESThPPAR, was transfected into the cells by using the Effectene transfection reagent (Qiagen, Hilden, Germany). The transfected cells were cultured in the maintenance medium for 24 h. The cells were then incubated in a growth medium which contained the test compound or DMSO. After an additional 48 h, total RNA was isolated as described later.
Luciferase reporter assay. An expression plasmid that contained the ligand-binding domain of human PPAR, _ , or fused to the GAL4 DNA-binding domain [pPPAR ( or )-GAL4] and the luciferase reporter plasmid, 17m2G TATA Luc (p17m2G), were kindly presented by Dr S. Kato (University of Tokyo, Tokyo, Japan). We transiently transfected COS-1 cells (5 Â 10 5 cells) with pPPAR ( or )-GAL4 (0.25 mg), p17m2G (1 mg), and the pSEAP-control vector (Clontech, CA, USA) by using the Effectene transfection reagent. Transfection was performed in 60-mm culture dishes, according to the manufacturer's instructions. After 16 h, the transfected cells were recovered and seeded into 96-well white multi-well plates, the indicated concentrations of the test compounds were added, and the plates were cultured for an additional 24 h at 37 C in a 5% CO 2 incubator. The luciferase activity and secreted alkaline phosphatase SEAP activity were measured in each well by using a Steady-Glo Ò luciferase assay (Promega, Madison, WI, USA) and Great ESCAPe SEAP Reporter System3 (Clontech), according to the manufacturer's instructions. The SEAP activity level was used to correct the luciferase activity in each well. Each data value is presented as the mean AE standard error of three experiments.
RT-PCR analysis. Total RNA (1 mg) was extracted by using an RNeasy Protect mini kit (Qiagen). First-strand cDNA was generated from total RNA by using random hexamers and Moloney murine leukemia virus (M-MLV) reverse transcriptase (Life Technologies, Luciferase/SEAP activity GW0742 G. mangostana pericarp extract (µg/mL) (nM) Fig. 1 . Activation by the G. mangostana Pericarp Extract of Peroxisome Proliferator-Activated Receptor (PPAR).
COS-1 cells were co-transfected with the luciferase reporter plasmid, p17m2G, which contained a GAL4 upstream-activating sequence in the promoter region, an expression vector for the human PPAR ligand-binding domain fused to the GAL4 DNA-binding domain, pPPAR-GAL4, and the secreted alkaline phosphatase control vector, pSEAP. The results are relative to the luciferase expression level which were normalized by using the secreted alkaline phosphatase (SEAP) activity. The G. mangostana pericarp extract and GW0742, a positive control PPAR agonist, were dissolved in dimethyl sulfoxide (DMSO) and added to the medium of the transfected cells. Each value is presented as the mean AE standard error of three experiments. TCA TCC ATG ACA ACT  TTG GTA TCG-3 0 , and reverse, 5 0 -GAG CTT GAC AAA GTG GTC GTT GA-3 0 . The thermal cycling conditions for PCR were 95 C for 1 min, followed by 28 cycles of 94 C for 40 s, 57 C for 40 s, and 72 C for 60 s. The mRNA expression levels were observed by using a transilluminator, after 2.5% agarose gel electrophoresis and staining with ethidium bromide.
Results

Activation of PPAR by the G. mangostana pericarp extract and -mangostin
The luciferase ligand assay using the GAL4/PPAR chimera system with COS-1 cells showed that the G. mangostana pericarp extract at a concentration of 10 mg/mL had approximately 1.7-fold luciferase activity relative to the vehicle control (Fig. 1 ). -andMangostins (Fig. 2) were the major constituents of the G. mangostana pericarps, and we evaluated their PPAR agonist activity. -Mangostin significantly activated approximately 2-fold luciferase activity at a concentration of 2.5 mM (Fig. 3) , whereas -mangostin had no activity at >2:5 mM and had cell toxicity at 10 mM (data not shown). 
Structure-activity relationship of the PPAR agonistic activities of a series of xanthone derivatives
To clarify the structure-activity relationships, the PPAR agonist activities of five xanthone derivatives were assessed; i.e., caloxanthone A, macluraxanthone, subelliptenone A, 12 -hydroxy-des-D-garcigerin, and harunganol B. The PPAR activation level ofmangostin was approximately 2-fold higher than those of caloxanthone A, macluraxanthone and 12 -hydroxy-des-D-garcigerin at a concentration of 2.5 mM. Subelliptenone A, harunganol B and -mangostin had no agonist activities at the same concentration (Fig. 4) . All these compounds indicated no cell toxicity at this concentration (data not shown).
Control of the expression of the UCP-3 gene in L6 cells by -mangostin
To elucidate whether -mangostin actually regulated the endogenous PPAR-response elements in intact cells, the expression level of the PPAR target gene, UCP-3, was measured in L6 myotubes in the presence of -mangostin. Figure 5 shows that the expression of UCP-3 was induced by adding 5 mM -mangostin, the induced expression being approximately equal to that of the UCP-3 gene in the presence of 0.1 nM GW0742.
Selectivity of -mangostin for the PPAR and PPAR agonistic activities
The selectivity of -mangostin for the PPAR and PPAR agonist activities was evaluated by using the luciferase reporter assay system. The 2.5 mM -mangostin level activated PPAR by almost the same amount as 50 mM Wy14643, a PPAR agonist (Fig. 6A) . However, the same concentration of -mangostin hardly activated PPAR compared with 10 mM troglitazone, a PPAR agonist (Fig. 6B) . and -mangostins (2.5 mM) were added to the medium of COS-1 cells transfected with pPPAR-GAL4 and p17m2G. GW0742 was also applied at a concentration of 0.1 nM. Each value is presented as the mean AE standard error of three experiments. L6 cells were treated with dimethyl sulfoxide (DMSO), 0.1 nM GW0742, or 5/2.5 mM -mangostin. Total RNA was prepared 48 h after adding the compound. The UCP-3 and GAPDH genes were amplified after cDNA synthesis, and the expression level was observed under a transilluminator after agarose gel electrophoresis and staining with ethidium bromide.
Induction by -mangostin of the expression of PPAR target genes in PPAR-expressing HepG2 hepatocytes
We studied whether -mangostin actually induced PPAR target gene expression in hepatocytes by performing a gene expression assay using transiently prepared PPAR-expressing HepG2 cells. These cells are wellcharacterized hepatocytes that are used for a gene expression analysis that depends on transfected PPAR activation. 15) Figure 7 shows that the acyl-CoA synthase and CPT1A expression levels were increased with 50 mM bezafibrate. Like bezafibrate, the addition of 5 and 2.5 mM -mangostin significantly induced acyl-CoA synthase and CPT1A expression.
Discussion
Many plants have an important role in maintaining animal and human health. In particular, herbs and functional foods have been used for medicinal purposes for a long time. In recent years, various nuclear receptors have attracted considerable attention because of their regulatory roles in the metabolic processes that affect glucose and lipid metabolism. 16) Compounds that regulate PPAR, , and , which are respectively related to fatty acid metabolism, obesity, and glucose homeostasis, have been the particular focus of further research. Many biologically active compounds with PPAR activities have therefore been purified and identified from natural resources. 17) Various PPAR modulators have been characterized. We verified in the present study the PPAR agonist activity of a G. mangostana pericarp extract, and identified -mangostin as one of the major constituents of its active compound. It has been reported that the content of -mangostin in an extract of G. mangostana pericarps was 5-10%; namely, that the concentration of -mangostin in 10 mg/mL of the extract was 1.25-5.0 mM. 18) These data and our data ( Figs. 1 and  3) indicate that almost all of the PPAR agonist activity exhibited by the G. mangostana pericarp extract was based on that of -mangostin.
-Mangostin is a xanthone derivative with two ,-dimethylallyl groups, and it has such reported bioactivities as anti-inflammatory, antibacterial, and anticancer effects. 9) However, there have been no reports on the PPAR agonistic activities of xanthone derivatives. Our results suggest that the presence of a more bulky substituted group such as a methoxyl (-mangostin) or _ ,-dimethylaryl group (subelliptenone A and harunganol B), rather than a hydroxyl group, at the C-7 position suppressed the PPAR agonist activity.
We have demonstrated in this study by using a reporter gene assay and RT-PCR that -mangostin had PPAR and PPAR agonistic activity. These results indicate that -mangostin acted as a PPAR agonist in myotubes and regulated UCP-3 expression which is involved in energy expenditure and fat metabolism. We have also shown that -mangostin regulated the promoters of PPAR target genes in intact HepG2 hepatocytes. Therefore, -mangostin was inferred to be a PPAR/ dual agonist. The development of this PPAR/ dual agonist is underway, and it may have such interesting properties as reducing dyslipidemia, insulin resistance, and reducing the atherogenesis risk. Wallace et al. showed in 2005 that T-659, a PPAR/ dual agonist, could increase the HDL level in primates. 19 ) HepG2 cells were transfected with pDEST-hPPAR, and then treated with dimethyl sulfoxide (DMSO) and 5/2.5 mM -mangostin after transfection. Total RNA was prepared 24 h after adding the compounds. The acyl-coA synthase, CPT1A, and GAPDH genes were amplified after cDNA synthesis, and the expression levels were observed under a transilluminator after agarose gel electrophoresis and staining with ethidium bromide.
In conclusion, our results suggest that -mangostin, which was obtained from G. mangostana pericarps, activated both PPAR and PPAR. This simultaneous activation of PPAR and PPAR by -mangostin may be an effective approach for treating the metabolic syndrome, in which lipid metabolism and obesity are both impaired. Xanthone derivatives containingmangostin should therefore be further investigated as therapeutic agents for treating the metabolic syndrome. More specifically, the anti-obesity and anti-hyperlipidemia effects of -mangostin should be evaluated in vivo, while the blood level of -mangostin needs to be determined and compared with the data in this study.
